Navigation Links
Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use
Date:5/30/2008

PRINCETON JUNCTION, N.J., May 30 /PRNewswire/ -- Lutronic, Inc., one of the world's leading developers and manufacturers of medical laser systems, announced today that its MOSAIC eCO2 system, the next generation in fractional resurfacing lasers combining fractional technology with the deep ablative features of a CO2 laser, is in its late stages of FDA review and clearance.

With intuitive touch-screen software, the powerful MOSAIC eCO2 features a contoured scanner hand piece with adjustable controls, enabling the practitioner to select various scanning patterns with different shapes and sizes. Unique patented intuitive software allows rapid selections between a continuous pulse, a randomized or sequential beam pattern, as well as penetrating or thermal type tip for patient-specific requirements and customized clinical results. Built-in "smart" fail-safes include sensor technology such as controlled chaos scanning technology (CCST) that minimizes double passing over previously treated skin as well as a hand piece / system interface that prevents the laser from firing unless the hand piece tip is in contact with the skin. In specific indications, the skin contact activated "repeat pulse" feature can be disabled converting the system to a standard "foot pedal" control device. Also featured is an energy-efficient, self-contained slim-line console with a maintenance-free articulated arm delivery system and convenient foot switch.

"The MOSAIC eCO2 is perhaps the most innovative and versatile multi-functional fractional CO2 laser system designed through not only extensive R&D, but doctor input and patient comfort optimization models as well," said Jhung-Won Hwang, Ph.D., Senior Director of Regulatory Affairs, Lutronic, Inc. "And, with our contemporary signature design, MOSAIC eCO2 is the easiest, most sophisticated, and highest quality laser system available today, delivering precision where it counts -- to the patient. Less pain, shorter downtime, and rapid recovery are the cornerstones to this vitally important addition to the Lutronic family of medical laser products."

MOSAIC eCO2 is designed to address a broad scope of clinical applications requiring the ablation, vaporization, excision, incision, and coagulation of soft tissue in dermatology and plastic surgery. A wide range of conditions may be treated with the highest degree of efficacy such as total skin resurfacing, treatment of fine wrinkles, rhytids, acne scars, surgical scars, and uneven pigmentation, such as lentigines and dyschromia.

The MOSAIC eCO2 Laser System utilizes a CO2 tube to generate a laser beam with a wavelength of 10.6 um. Taken together with the unique scanner hand piece, the physician can optimize the effect for different applications by controlling the power of the laser pulse and using a different scan pattern.

"The main differentiating feature of the MOSAIC eCO2 system is the 'freedom' it brings to the practitioner as well as to the patient: freedom from inferior fractional laser systems; freedom from painful treatments and questionable results; freedom to self-select depth and density of treatment; and freedom to select Static and Dynamic modes to deliver the very best results possible.

"The ability to combine two operation modes in one delivery system is particularly important when comparing MOSAIC eCO2 to other fractional CO2 lasers," continued Dr. Hwang. "Static mode offers deeper penetration and greater patient comfort, and Dynamic mode is ideal for larger area blending and smoothing. The laser works exceptionally well in medical applications because 10.6 um is near the peak of tissue water absorption, and when water in the tissue absorbs the laser energy, it heats up. This heating causes instantaneous vaporization of the target tissue. This smart system is yet another example of Lutronic's tireless efforts as the vanguard in breakthrough aesthetic and clinical laser technology."

About Lutronic

Lutronic is one of the world's leading developers and manufacturers of medical laser systems serving the clinical dermatological and aesthetic communities. With over a decade of award-winning technology design that includes its Spectra line of products and its unparalleled MOSAIC Systems, the company is committed to delivering innovative, highly effective, and painless laser solutions. In addition, Lutronic, Inc. offers an impressive service department featuring experienced laser engineers who provide the highest level of service and support to physicians across the US. Manufacturing medical laser systems for markets in Europe and Asia, parent Lutronic Co. Ltd. is based in Seoul, South Korea and delivers products to over 40 countries. To learn more about the MOSAIC eCO2 Laser System, please visit http://www.lutronic.com.

Contact:

Ken Reich

Director, Marketing & Public Relations

Lutronic, Inc.

Phone: 609 275-1565 x302 or 888 588-7644

Fax: 609 275-3800

Email: kreich@lutronic.com

This release was issued through eReleases (TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Lutronic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New Medicare and Medicaid Data Released: Featuring Up-To-Date Enrollment Trends, State Initiatives, Regional Market Share and Prescription Drug Benefits
2. Lutronic Inc. Announces FDA Clearance of Its Spectra VRM III Q-Switched Nd: Yag Laser System for Treating a Broad Spectrum of Dermatological and Aesthetic Conditions
3. Elbit Imaging Ltd. Announces First Quarter Results for 2008
4. ASTRO announces 2008 gold medalists
5. Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008
6. Darwin Announces Creation of New Health Care and Errors and Omissions Divisions
7. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
8. Ekahau Announces Compatibility With 802.11n
9. Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
10. DRAXIS Announces Completion of Sale to Jubilant
11. WellPoint Announces Realignment of Operations, Technology and Government Services Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, and the ... results and maintaining GMP and USP compliance. In a new webinar from METTLER ... requirements " these requirements are explained. The challenge is to determine how ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... With less ... from acne, access to quality care can be limited while the desire to conquer ... offers customized prescription acne care for every customer online, today released its inaugural survey ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Columbus OH. Dr. ... as one of few medical professionals in the country to sit on the 2017 ... Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a ...
(Date:3/28/2017)... ... March 28, 2017 , ... Public relations pros work ... a variety of business channels. , While many results are clear, much of PR ... program. , When it comes to measurement, firms should always take an all-inclusive ...
(Date:3/28/2017)... ... ... skin is a common and unwelcomed occurrence in people of all ages, genders and ethnicities. ... the discussion of dealing with excess skin oil. “Oily skin is a challenge to many ... help remove the oily shine while keeping the skin fresh and clean,” says Dr. Au. ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... Elysium Health joins major pharmaceutical companies to ... Cambridge academic scientists through ... Institute today announces Elysium Health as a partner to the ... collaborative projects with academic researchers in Cambridge ... major research investment outside the U.S. for the ...
(Date:3/27/2017)... Summary This report provides all the information ... interests and activities since 2010. Description The Partnering Deals ... the partnering activity of one of the world,s leading life ... upon purchase to ensure inclusion of the most up to ... be delivered in PDF format within 1 working day of ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: ... immunotherapy successfully passed early toxicology and efficacy studies. The ... to target a specific protein, MAGE A, in an ... breast cancer. After 4 weeks of ... to show very little toxicity in a full toxicology ...
Breaking Medicine Technology: